Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review

Raja Nur Firzanah Syaza Raja Sharin, Jesmine Khan, Mohamad Johari Ibahim, Mudiana Muhamad, Joanne Bowen, and Wan Nor I’zzah Wan Mohamad Zain

Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, 47000 Sungai Buloh, Selangor, Malaysia
Discipline of Physiology, School of Biomedicine, University of Adelaide, South Australia 5005, Australia

Correspondence should be addressed to Wan Nor I’zzah Wan Mohamad Zain; wnizzah@uitm.edu.my

Received 20 March 2022; Accepted 14 June 2022; Published 28 June 2022

Lapatinib, an orally administered small-molecule tyrosine kinase inhibitor (SM-TKI), is an effective treatment for ErbB2-positive breast cancer. However, its efficacy as one of the targeted cancer therapies has been hampered by several adverse effects, especially gastrointestinal toxicity, commonly manifested as diarrhoea. Although it can be generally tolerated, diarrhoea is reported as the most common and most impactful on a patient’s quality of life and associated with treatment interruption. Severe diarrhoea can result in malabsorption, leading to dehydration, fatigue, and even death. ErbB1 is an epidermal growth factor profoundly expressed in normal gut epithelium while lapatinib is a dual ErbB1/ErbB2 tyrosine kinase inhibitor. Thus, ErbB1 inhibition by lapatinib may affect gut homeostasis leading to diarrhoea. Nevertheless, the underlying mechanisms remain unclear. This review article provides evidence of the possible mechanisms of lapatinib-induced diarrhoea that may be related to/or modulated by ErbB1. Insight regarding the involvement of ErbB1 in the pathophysiological changes such as inflammation and intestinal permeability as the underlying cause of diarrhoea is covered in this article.

1. Introduction

Diarrhoea is a common gastrointestinal (GI) toxicity that is associated with a wide range of cancer treatments. In particular, receptor tyrosine kinase inhibitors (TKIs) directed against the epidermal growth factor receptor (EGFR) have diarrhoea as a class effect while diarrhoea induced by chemotherapy is not exclusively an epithelial effect but rather a complicated interaction between all mucosal compartments [1]. Nevertheless, no clinical guidelines are designed specifically for the management of TKIs-induced diarrhoea [2], contradictory to chemotherapy-induced diarrhoea which has several guidelines, including from the European Society for Medical Oncology (ESMO) and US National Comprehensive Cancer Centre Network [3]. This lack of clinical guideline was attributable to limited investigations on the underlying mechanisms of diarrhoea induced by targeted drugs. Thus, the treatment management of TKIs follows the management of chemotherapy-induced diarrhoea [4]. Although it can be abided, diarrhoea can affect about 50% to 80% of patients, depending on the treatment strategy [5].

Severe diarrhoea can cause dehydration, malabsorption, fatigue, bowel discomfort, and perianal skin breakdown [6]. Furthermore, administration of small-molecule tyrosine kinase inhibitors (SM-TKIs) as cancer targeted therapies is prescribed for longer duration; thus, diarrhoea is often prolonged, which significantly compromises the quality of life (QOL) of patients with cancer. Indisputably so, effective treatment strategies for SM-TKIs-induced diarrhoea are critically needed, towards immediate identification of appropriate mechanisms of SM-TKIs-induced diarrhoea.

Lapatinib is an orally administered, dual ErbB1 and ErbB2 TKI and proven effective in treating ErbB2-positive...
breast cancer. Lapatinib reversibly binds to the intracellular adenosine triphosphate- (ATP-) binding site of the tyrosine kinase domain and prevents receptor phosphorylation and activation, hence blocking downstream signalling pathways such as mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) and phosphatidylinositol-3′-kinases (PI3K)/Akt pathways which are involved in cell survival and proliferation, respectively [7]. In other words, the mechanism of action of lapatinib is by inhibition of ErbB1 and ErbB2 kinase activity, thus preventing the activation of downstream cellular signals that promote tumour cell survival and proliferation.

Despite its success as an ErbB2-positive breast cancer treatment, lapatinib has raised concern on gastrointestinal toxicity, specifically diarrhoea, which affects 78% of patients [8]. Several possible aetiologies have been hypothesised and discussed to account for lapatinib-induced diarrhoea. Leading theories investigated in preclinical models relate to alteration of chloride secretion and intestinal histopathological changes in the gastrointestinal tract (GIT) [8–10]; however, none of these studies were able to conclude a solid rationale for the mechanism of lapatinib-induced diarrhoea. Previous studies in particular have shown that inhibition of ErbB1 resulted in intestinal atrophy in mice by a loss of epithelial length [11], nutrient and electrolyte transport, and brush border enzyme expression [12]. Meanwhile, other studies using lapatinib in tumour-bearing models showed no evidence of histopathological changes at all, making this pathogenesis of diarrhoea remain unclear.

Thus, in this article, the possible underlying mechanisms of lapatinib-induced diarrhoea pertaining to ErbB1 involvement in inflammation and intestinal permeability based on in vitro and in vivo studies which may contribute to changes in intestinal health were discussed in detail. The associations between lapatinib and diarrhoea and how ErbB1 inhibition leads to intestinal inflammation and permeability were outlined. The inclusion criteria for the studies were (i) incidence of diarrhoea related to SM-TKIs, (ii) lapatinib gastrointestinal toxicity, and (iii) SM-TKIs affecting gastrointestinal changes from year 2005 to 2021, using the Boolean operator “AND.” The keywords used during the search were lapatinib and “diarrhoea/diarrhoea”, EGFR/ErbB1 and “intestinal inflammation”, EGFR/ErbB1 and “intestinal permeability”, and EGFR/ErbB1 and “intestinal tight junction”. A total of 60 articles were included in this narrative review, while the rest were excluded due to repetitive experiments, review articles, and some articles being not totally related to the search topic.

1.1. ErbB Family Receptors. The ErbB family of tyrosine kinase receptors are cell surface receptors, with four types of proteins which are EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/HER3, and ErbB4/HER4. All these proteins are important in regulating cell proliferation, differentiation, migration, and opposing cell death [13]. Each of the ErbB members exists as monomeric receptors [14]. Upon activation, these receptors can form ten different homodimers and heterodimers, initiating multiple signalling pathways such as ERK/protooncogene protein P21 (ERK/Ras), PI3K/Akt, phosphoinositide phospholipase C-γ1 (PLCγ1), and signal transducer and activator of transcription proteins/STAT (STAT/Src) [15, 16].

ErbB2 does not contain a ligand-binding domain, yet ErbB2 appears to be the preferred binding partner to its family members, as its dimerization arm is constitutively exposed. ErbB3 does not contain a kinase domain; therefore, ErbB3 homodimers possess little autophosphorylation activity. However, ErbB3 can still be phosphorylated and induce potent downstream. ErbB1 on the other hand has six other ligands in addition to epidermal growth factor (EGF) which are transforming growth factor-alpha (TGF-α), amphiregulin (AREG), epiregulin (EREG), betacellulin (BTC), heparin-binding EGF-like growth factor (HB-EGF), and epigenin (EPI). Both ErbB1 and ErbB4 are targeted by BTC, HB-EGF, and EREG. Notably, another ErbB ligand, neuregulins (NRGs), can bind both ErbB3 and ErbB4 or only ErbB4 [17].

In healthy tissues, ErbB members are expressed in the brain, skin, lung, and GIT [17]. However, several studies have reported that overexpression of ErbB family members, especially ErbB2 either in vitro or in vivo, leads to cell transformation and metastasis [18]. Meanwhile, overexpression of ErbB1 has been correlated with gastric cancer, human hepatocellular carcinoma, and oesophageal cancer [19], and ErbB3 has been implicated in breast, bladder, and gastric cancers [13], whereas ErbB4 is also commonly associated with gastrointestinal cancer [20]. As such, inhibition of ErbB members and their downstream signalling provides a therapeutic option against human tumours with overexpression of ErbBs.

Specifically, all these ErbBs can be found abundantly in small intestinal cells but have lower expression in Paneth cells [21]. However, a study using single-cell mapping showed no expression of ErbB4 throughout the epithelium [22], but both EGF and NRG1-expressing cells were identified in the developing human intestinal tract, with EGF being found in the epithelial villus domain and NRG1 being discovered in cells inside the subepithelial mesenchyme underneath the crypts [23].

ErbB1 promotes intestinal restitution/wound healing, cell survival, ion transport, and other essential elements of mucosal cell physiology. Reports comparing ligands with different receptor specificity define different outcomes. For example, ErbB1/ErbB4 ligands such as HB-EGF promote intestinal cell migration and proliferation, while NRG4 stimulates only cell survival [24]. Numerous studies especially in vitro and in vivo clearly concluded that ErbB1 activation necessitates protective responses in inflammatory bowel disease (IBD) models. Besides, the effects of probiotic organisms such as Lactobacillus rhamnosus GG against dextran sulphate sodium- (DSS-) induced colitis also depend on ErbB1 activity. Similarly, activation of ErbB4 showed protective effects on the epithelium; for instance, intraperitoneal NRG4 administration blocks cytokine-induced colonic crypt apoptosis and reduces histopathological damage in the DSS-induced colitis model. Loss of ErbB4, however, sensitizes epithelial cells to tumour necrosis factor-induced death [25].
The role of ErbB1 has also been studied extensively in the regulation and maintenance of the intestinal stem cell (ISC) niche. Several investigators showed that ErbB1 is crucial for ISC proliferation but not differentiation. In contrast, others reported that it does in fact involve both. However, a bacterial infection-induced injury study reported that ErbB1 is involved in differentiation and/or proliferation and cell shedding to remodel and maintain the homeostasis of the gut lining after the injury. This process perhaps involves reducing the cell number, shortening the gut and its elongation, increasing the number of differentiated cells, and then replenishing the ISC compartments in a nicely orchestrated manner at specified time points [26].

In cultured intestinal cells, activation of ErbB promotes cellular outcomes that would be anticipated to be protective during inflammation. In colon epithelial cells, for example, ErbB1 increases proliferation, decreases cytokine-induced apoptosis, and promotes migration/wound healing both in vitro and in vivo. Specific ligand/receptor combinations can elicit selective responses; for example, NRG4, which selectively activates ErbB4, signals for mouse colonocyte survival but not proliferation or migration. This implies that with a greater knowledge of the relative effects of various ligands and receptors, a substantial degree of selectivity in response may be gained [27].

Both ErbB2 and ErbB3 are detected throughout the crypt-villus axis [22]. Determination of ErbB2 and ErbB3 roles in the intestine has been augmented by numerous studies, with various hypotheses being reached. Although no ligands have been identified for ErbB2, its activation can be induced by heterodimerization with ligand-occupied ErbB1, ErbB3, or ErbB4. ErbB2 has been implicated in mediating myoblast cell survival and in inhibiting cancer cell apoptosis [17]. In addition, ErbB2 has been shown to be transactivated by tumour necrosis factor-alpha (TNF-α), which in turn protects intestinal epithelial cells from TNF-α-induced apoptosis.

Even though ErbB3 homodimers possess little autophosphorylation activity, however, ErbB3 is often overexpressed in colorectal cancers when associated with ErbB1 and ErbB2. Intestine-specific ErbB3 ablation showed more damage to colonic epithelial cells and slow recovery of epithelial cells in a model of colitis induced by dextran sulphate sodium (DSS) [28]. Moreover, in a mutant allele of murine Apc (adenomatous polyposis coli) (Apc<sup>min</sup>) intestinal tumour mouse model, intestine-specific ErbB3 knockout mice have less cellular proliferation within polyps in the intestine than the control mice [28].

1.2. ErbB1 Inhibition as Targeted Therapeutic for Cancer. ErbB1/EGFR/HER1 is a 170 kDa transmembrane glycoprotein that is composed of a single polypeptide chain and can either form homodimers or heterodimers with other ErbB members, ErbB2, ErbB3, and ErbB4. It has the largest number of signalling which includes ERK/MAPK, PI3K/Akt, SRC, PLCγ1/PKC, JNK, and JAK/STAT pathways [13], thus generating various diversity of cellular responses including cell proliferation, differentiation, apoptosis, and mortality [29]. Nonetheless, overexpression of ErbB1 was elucidated in several cancers such as colon, breast, and brain [30], rendering blockade of ErbB1 as a viable therapeutic option for the treatment of those tumours.

ErbB1 targeted therapies can be divided into monoclonal antibodies (mAbs) and single-targeted TKIs, dual-targeted TKIs, and multitargeted TKIs (generally known as SM-TKIs). mAbs that have been authorised for clinical use include cetuximab, panitumumab, nimotuzumab, and necitumumab, which are intended to selectively attach to the epitopes expressed on tumour cells in a distinct manner [31]. Specifically, they were generated against the ErbB1 receptor’s ligand-binding extracellular domain and compete with ErbB1 ligands such as EGF to inhibit phosphorylation and activate ErbB1-associated kinases [31]. As such, these will inhibit cellular growth and activation of apoptosis and decrease the growth factor production [32]. In addition, mAb is reported to have a higher affinity towards ErbB1 and possesses a longer half-life (e.g., 7.5 days for panitumumab) compared to SM-TKI (e.g., 48 hours for gefitinib) [33], making it more potent as an ErbB1 inhibitor. The drugs are administered intravenously.

In contrast, SM-TKIs are designed to bind directly to the ATP-binding site in the kinase domain of ErbB1 receptors and abolish their intracellular kinase activity [34]. Single-target TKIs such as gefitinib and erlotinib could bind only one tyrosine kinase inhibitor. Lapatinib a dual-target TKI pursues ErbB1 and ErbB2 simultaneously, thus indirectly inhibiting both phosphorylation and downstream signal transduction such as PI3K and MAPK pathways [35]. Additionally, multitargeted TKI drugs such as afatinib and dacomitinib target several tyrosine kinase receptors simultaneously through inhibition of cell proliferation and differentiation such as PLCγ and Wnt pathways [36]. Even though SM-TKIs have a short half-life, these orally active agents are suitable for long-term therapy.

Noted that, all these TKIs also differ in terms of their pharmacokinetics, which depends on the drug absorption, metabolism, and distribution and can be affected by pharmacogenetic of patients’ background [33]. It is imperative to state that the distribution and metabolism between SM-TKIs and mAbs showed different mechanisms and molecular characteristics. Panitumumab, for instance, is administered at 6 mg/kg every 2 weeks, with typical absolute systemic availability of 70% [37]. It is mainly distributed into vascular space, which is able to prolong survival in patients with metastatic colorectal cancer. Meanwhile, the typical absolute systemic availability following oral treatment is 103.8% [38]. Gefitinib is likely to pass the blood-brain barrier, which might be beneficial in individuals with metastatic illness. It reaches steady-state concentrations in about 10 days. In short, SM-TKI is rapidly absorbed and distributed in large amounts (volume of distribution (Vd) > 100 L) compared to mAb which is distributed to the tissue slowly due to its large size (Vd < 10 L) [39]. In terms of metabolism, cytochrome P450 (CYP) 3A4 is primarily responsible for the SM-TKI oxidation and reduction process which resulted in renal elimination in urine and conjugation processes leading to hepatic/biliary elimination in the stool [40]. Meanwhile, mAbs are degraded into peptides and
Diarrhoea has been reported as the most common adverse effects (AEs) associated with ErbB1 targeted SM-TKIs. However, SM-TKIs have a notable benefit over mAbs in that they are available orally and allow for more convenient administration as compared to intravenous infusion, which requires outpatient visits.

1.3. Incidence of Diarrhoea Associated with ErbB1 Targeted Drugs. Diarrhoea has been reported as the most common adverse effect of ErbB1 targeted SM-TKI agents after rash and frequently affects the rapidly dividing cells of the intestinal epithelium. It can be debilitating and lead to life-threatening adverse effects when it occurs in combinations with other complications such as neutropenia and cardiovascular morbidity [42]. Diarrhoea occurs approximately on day 7 of the treatment period, especially for multi-ErbB SM-TKI, with a common presentation of mild diarrhoea (grade 1-2). Noted that, mild diarrhoea should be considered an imperative case as prolonged diarrhoea affects patients’ QOL. A previous clinical study using neratinib, an example for multi-ErbB SM-TKI, has shown that about 40% of severe diarrhoea (grade 3-4) incidence has been reported among 1408 patients. Meanwhile, lapatinib-induced diarrhoea showed a higher percentage among other first-generation TKIs, about 25% (Table 1). Diarrhoea can be caused by ErbB inhibitors alone or related to the combination treatment with chemotherapy. Furthermore, recent clinical studies have shown that all grades of diarrhoea are more commonly seen with second-generation pan-ErbB SM-TKIs rather than first-generation ErbB SM-TKIs. Even though it can be said that single-target TKIs would offer a greater chance of treatment compared to other multitargeted TKIs, it might be limited to this statement of whether all kinases have equal contribution to carcinogenesis [43]. Besides, there is a possibility that some receptor tyrosine kinases in healthy cells would also be inhibited by these multi-TKIs due to their unspecific TKI binding [43], thus leading to a new concern on classical toxicities of these compounds such as diarrhoea, rashes, and, even worse, cardiovascular toxicity [44]. In general, understanding of the TKIs-induced diarrhoea mechanism allows a cautious optimism to further enrich the therapeutic armamentarium against this side effect, hence improving the QOL of patients with cancer.

1.4. Treatment of Diarrhoea Associated with ErbB1 Targeted Drugs. In general, management of cancer therapy-adverse effects (AEs) should consist of prophylactic measures, supportive medications, treatment delays, and dose reductions. The American Society and Clinical Oncology (ASCO) together with the European Society for Medical Oncology (ESMO) have established several consensus guidelines for cancer treatment-induced diarrhoea. The approach to diarrhoea management is based on severity and complication level, which includes hospital admission and self-administered anti-diarrhoeal agents such as loperamide and octreotide to regulate gut motility and administration of intravenous fluids [58]. Loperamide is a synthetic opioid which agonizes opioid receptors present in the gastrointestinal tract [59]. There are several mechanisms of action of loperamide which reduce the peristalsis, increase gut transit time, and promote fluid absorption. Loperamide can be considered a conventional diarrhoea treatment; however, the efficiency as the first-line therapy for diarrhoea patients has been associated with other consequences, such as severe constipation and nausea [3]. Besides, prolonged use of high doses of loperamide for diarrhoea treatment can cause prolonged corrected QT interval (QTC) and provoke life-threatening arrhythmias, such as ventricular fibrillation [60]. Thus, octreotide becomes the second choice when loperamide fails. This can be a plausible merit to investigate new target treatments for ErbB1 TKI-induced diarrhoea. However, targeting interventions that effectively prevent or manage ErbB1 TKI-induced diarrhoea can only be achieved by understanding the underlying mechanisms.

1.5. Roles of ErbB1 in the Possible Mechanisms of Lapatinib-Induced Diarrhoea

1.5.1. Lapatinib. Lapatinib (GW-572016) is a novel member of the 4-anilinoquinazoline class of kinase inhibitors which consist of a large aniline quinazoline head group, thus enhancing deep access into the catalytic cleft of ErbB1 [2]. The drug reversibly binds to the intracellular ATP-binding cytoplasmic domain of tyrosine kinase receptor thus blocking the receptor leading to activation of certain pathways including PI3K/Akt, MAPK [61], and PLCγ by decreasing the phosphorylation of the targeted receptor and Raf, Erk, Akt, and PLCγ1 proteins [62]. Lapatinib is a potent, reversible, and selective dual inhibitor of EGFR and ErbB2 kinases [63]. Xiang et al. reported the half-maximal inhibitory concentration (IC50) of lapatinib in nineteen tumour cells of gastric cancer, melanoma, hepatocarcinoma, thyroid, breast, pancreatic, and colorectal cell lines. This study revealed that proliferation IC50 values were <8μM, showing different degrees of lapatinib sensitivity. All these cell lines were then divided into two groups, high-IC50 and low-IC50 by taking IC50 as the threshold to observe the ErbB1 and ErbB2 expression. It was noted that expression of ErbB1 and ErbB2 was significantly higher in the low-IC50 group (IC50 < 8μM), thus concluding that lapatinib sensitivity is positively correlated with the ErbB pathway [64]. Lapatinib was approved by the Food and Drug Administration (FDA) in 2007, as a second line for ErbB2 metastatic breast cancer, along with capcitabine [65], a produg of fluorouracil which has high absorption in GIT [66]. The approved dose for lapatinib is 1,250 mg per day, five 250 mg tablets per day taken continuously along with capcitabine 2,000 mg/m² per day during days 1–14 of each 21-day treatment cycle [4].

1.5.2. Lapatinib and Diarrhoea. Like other TKIs, lapatinib does not just impose diarrhoea [12, 61, 67, 68], along with hypertension [67] and rash that tends to be localized most frequently on the trunk but infrequently on the face [2]. Although diarrhoea seems common, it is often severe enough to require a break in treatment or a dose reduction [6]. Diarrhoea in lapatinib administration was evident as...
early as 7 days of the treatment course and has been managed usually with antidiarrhoeal agents depending on the treatment protocol [69]. However, it is hypothesised that the development of lapatinib-induced diarrhoea differs from conventional chemotherapy-induced diarrhoea and is not due to direct cytotoxicity but through alternative mechanisms [70]. Thus, traditional diarrhoea management may not be targeting the underlying changes for optimal management.

Various hypotheses have been reported regarding the underlying mechanism of lapatinib-induced diarrhoea such as alteration of chloride secretion in the gut lumen and changes in gut microflora, and the most notable theory is inhibition of ErbB1 in gastrointestinal mucosa. ErbB1 is expressed in GI mucosa which is the primary site for the drug absorption in the intestine. Thus, the administration of ErbB1 SM-TKI may interfere with normal functioning, leading to diarrhoea.

One such hypothesis theorized that diarrhoea from ErbB SM-TKIs is a form of secretory diarrhoea, activated by apical chloride channels such as calcium-activated chloride channels (CaCC) and cystic fibrosis transmembrane conductance regulator (CFTR) [71]. In this mechanism, the chloride channels increase the fluid secretion into the lumen, thereby

| Type of ErbB1 TKI       | Receptor binding | Target                                | Indication                                      | Route of administration | Diarrhoea incidence, All grades (%) | Severe grade 3-4 (%) | References |
|-------------------------|------------------|---------------------------------------|------------------------------------------------|-------------------------|------------------------------------|----------------------|------------|
| Monoclonal antibodies (mAbs) |                   |                                       |                                                |                         |                                    |                      |            |
| Cetuximab (Erbitux*/C225) | Irreversible     | Extracellular domain III of ErbB1     | HNSCC, metastatic colorectal cancer            | Intravenous             | 3%                                 | 1.7%                 | [45]       |
| Panitumumab (Vectibix*)  | Irreversible     | Extracellular domain III of ErbB1     | Metastatic colorectal cancer, solid tumours    | Intravenous             | 20%                                | 1.3%                 | [46]       |
| Nimotuzumab (h-R3)       | Irreversible     | Competitive binding to extracellular domain III of ErbB1 (353–358) with ligand | HNSCC, metastatic pancreatic cancer, oesophageal cancer, gastric cancer | Intravenous             | 2.73%                              | 0.91%                | [47]       |
| Necitumumab (Portrazza™) | Irreversible     | Competitive binding to extracellular domain III of ErbB1 (384–409) with ligand | NSCLC, solid tumours                           | Intraoral               | 7%                                 | 2%                   | [48]       |
| First generation Erlotinib (Tarceva*) | Reversible | ErbB1                                  | NSCLC, pancreatic cancer                       | Oral                    | 43.4%–69.2%                       | 1%–17%               | [49–51]    |
| Gefitinib (Iressa*)      | Reversible       | ErbB1                                  | NSCLC                                          | Oral                    | 35.7%–56%                         | 1%–3.8%              | [42, 50]   |
| Lapatinib (Tykerb/ Tyverb*) | Reversible      | ErbB1, ErbB2                          | Breast cancer                                  | Oral                    | 58%–78%                           | 23.3%–25%           | [8, 52]    |
| Second generation Neratinib (Nerlynx*) | Irreversible | ErbB1, ErbB2, ErbB4                   | ErbB2-positive breast cancer                   | Oral                    | 95%                                | 39.8%                | [53]       |
| Afatinib (Giotrif*)      | Irreversible     | ErbB1, ErbB2, ErbB3, ErbB4            | NSCLC                                          | Oral                    | 42%–92.9%                         | 10%–16%              | [50, 54]   |
| Dacomitinib (Vizimpro*)  | Irreversible     | ErbB1, ErbB2, ErbB4                   | NSCLC                                          | Oral                    | 87%                                | 8%                   | [55]       |
| Third generation Osimertinib (Tagrisso*) | Irreversible | T790M ErbB1 mutation                  | NSCLC                                          | Oral                    | 47%–58%                           | 2%–3.3%              | [42, 56]   |
| Tucatinib (Tukys*)       | Reversible       | ErbB2                                  | ErbB2-positive breast cancer                   | Oral                    | 81%                                | 12.5%                | [57]       |

Abbreviation: HNSCC: head and neck squamous cell carcinoma; NSCLC: non-small-cell lung cancer; T790M: Threonine790Methionine mutation.
inhibiting the absorption of intestinal sodium, which reduces overall fluid absorption. It has been reported that ErbB1 has an inhibitory effect on chloride secretion in the small intestine, which raises the hypothesis that inhibition of ErbB1 in the intestine allows the excessive chloride secretion into the gut lumen. An *in vitro* study has evidenced that dacomitinib, a pan-ErbB TKI, increased intestinal epithelial chloride secretion [72]. Moreover, previous studies using an *in vivo* model on dacomitinib and neratinib-induced diarrhoea suggested that the diarrhoea was secretory in nature. However, treatment with an anti-diarrhoeal agent, crofelemer, which is also an antichloride secretory mediation on *in vivo* model-induced dacomitinib worsened diarrhoea levels [73]. Studies on chloride secretion following lapatinib and neratinib in a rat model show no evidence of change, thus leaving the role of chloride secretion unclear [53, 70] with major discordance in findings between *in vitro* and *in vivo* settings.

Aside from ErbB1-induced alterations in chloride secretion, direct damage to the GI mucosa by the oral administration of ErbB1 SM-TKIs has been reported. Studies using ErbB1 knockout mice and other ErbB1 SM-TKIs have described mucosal atrophy supporting a role for direct mucosal damage [74, 75]. Besides inhibiting tumour cell survival and proliferation, ErbB1 SM-TKIs are also said to inhibit the normal function of ErbB1 in the gastrointestinal mucosa. This is shown by a study by Secombe et al. who found decreased activation of ErbB1 in rat models after treatment with neratinib [76]. A recent study also has shown that ErbB1 SM-TKI-induced diarrhoea resulted from histopathological damage which was evidenced by significant growth reduction and villi atrophy in the ileum [72]. In contrast, studies using lapatinib in tumour-bearing models did not show any histopathological changes [70], thus making the mechanism of ErbB1 inhibition-induced diarrhoea unclear.

Besides the above hypotheses, another impetus for further investigation is whether ErbB1 SM-TKIs cause inflammation. A study using a TKI-induced diarrhoea model in 2019 has proved a decrease in diarrhoea incidence following neratinib when rats were treated with budesonide and colesevelam, in which both are used as anti-inflammatory agents in gastrointestinal conditions [76]. This result then was supported by increasing levels of interleukin-4 (IL-4), an anti-inflammatory interleukin in both the colon and ileum of budesonide-treated rats. In addition, there are also increased responses of inflammatory cytokines such as interferon-alpha (IFN-α) and interferon-gamma (IFN-γ) observed in both *in vitro* and tumour-bearing models treated with osimertinib [77]. One study by Lacouture et al. revealed that panitumumab-treated patients were able to suppress diarrhoea incidence to 56% compared to the reactive arm (85%) when administered with doxycycline as an anti-diarrhoeal agent [78]. Note that doxycycline, an antibiotic, exhibited anti-inflammatory properties. Even though this is not a direct study of TKI-diarrhoea-induced inflammation, Lacouture et al. [78] later suggested that diarrhoea induced by ErbB1 might involve an inflammation process.

A study by Leech et al. in 2018 on lapatinib-treated cells showed lower expression of junction adhesion molecule-A (JAM-A), a tight junction protein (TJP) that is highly expressed in normal epithelial and endothelial cells. This showed that administration of lapatinib does increase intestinal permeability by compromising TJP integrity [79]. Additionally, an increase in permeability initiates recruitment of lipopolysaccharides (LPS) from the small intestinal lumen, promoting inflammatory cytokines to stimulate an immune reaction, thus activating inflammatory reaction [80]. These studies showed that lapatinib might induce diarrhoea by increasing the permeability of intestinal TJPs, thereby promoting inflammation.

In a dacomitinib-induced diarrhoea rat model, cytoplasmic redistribution of claudin-1 was seen in the ileum of the drug-treated rats, where peak histopathological damage such as blunting and villi fusion were observed. Inflammatory infiltrate was also noted in the ileum suggesting that the tight junction dysfunction can be proinflammatory cytokine-mediated [73]. Tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and IL-6 also have been shown to contribute to the severity and degree of injury in chemotherapy-induced gut toxicity [81]. These studies emphasized the importance of the integrity of the structure and function of tight junction proteins of intestinal epithelial cells in the downstream signalling of ErbB1. As such, it is said that inflammation may impact the tight junctions which are also potential mechanisms leading to the diarrhoea in ErbB1 TKI-treated patients. Another potential avenue that could be associated with the oral-administered drug is the accumulation of unabsorbed drugs in the lumen due to its low bioavailability, thus leading to mucus secretion and therefore resulting in the osmotic movement of water in diarrhoea [82].

Based on this previous literature, the complex relationship between compromised gut wall integrity and mucosal inflammation has sparked scientific interest in various inflammatory bowel studies. However, it is unclear whether a damaged mucosal barrier promotes intestinal inflammation or whether poor barrier function is a side effect of the inflammatory process. Nonetheless, there is a well-established relationship between increased intestinal permeability and increased inflammatory activity. Together, these studies provide important insights to further enrich the understatement of lapatinib-induced diarrhoea mechanism. A conceptual framework was constructed (Figure 1) directing the concept that once administered, lapatinib binds to the intracellular ATP-binding site of the tyrosine kinase domain and inhibits receptor phosphorylation and activation. The drug then not only inhibits tumour cell survival and proliferation but also inhibits ErbB1 function in the GI mucosa. Inhibition of ErbB1 function disrupts gut homeostasis causing inflammation to the intestinal monolayer which leads to disruption of TJPs further adding to increased intestinal permeability, hence diarrhoea.

1.5.3. ErbB1 and Inflammation in TKIs-Induced Diarrhoea. Inflammation is known as one of the key roles in the development of gastrointestinal problems, in which it is also
believed to be involved in SM-TKIs-induced diarrhoea. Development of SM-TKIs-induced diarrhoea is said to differ from conventional chemotherapy-induced diarrhoea (CID) since it does not involve direct cytotoxicity [70, 72]. Thus, in the literature on SM-TKIs-induced inflammation, the relative importance of chemotherapy-induced inflammation has been subjected to considerable discussion.

Several studies have documented that the chemotherapy-induced diarrhoea mechanism involves regulation of 5-fluorouracil (5-FU), irinotecan, and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN38) [3]. Histological intestinal damage such as blunting villi, crypt ablation, and excessive mucus secretion [83] in a mouse model was evidenced from CID. It is also strongly believed that CID is associated with GI mucositis which can be divided into 5 sequential phases: initiation, upregulation, signalling and amplification, ulceration and inflammation, and healing [3]. In this context, the initiation phase involves initiation injury to tumour cells caused by chemotherapy and radiation, either directly through DNA damage or, more common, indirectly through reactive oxygen species. This causes a cascade of enzyme and transcription factor activation (e.g., nuclear factor, NF-κβ), which leads to the activation of inflammatory cytokines such as TNF-α, IL-1, and IL-6, which resulted in tissue damage in submucosa and basal epithelium, hence leading to ulceration and bacterial colonisation, perpetuating a vicious cycle of inflammatory cytokine-mediated harm [84]. This will eventually thin the mucosal barrier, which allows bacterial translocation and malabsorption thus resulting in diarrhoea [5]. The healing phase then involves signalling via the extracellular matrix which stimulates epithelial proliferation and epithelization, as such reestablishing the mucosal barrier. In addition, the latest study by Wardill et al. showed that activation of toll-like receptor (TLR) by irinotecan also attenuates the upregulation of the inflammation process in CID [85]. As such,
CID is described to have a direct tissue damage mechanism, which differs from SM-TKIs that might involve indirect biological signalling.

Recent studies of ErbB1 TKIs reported that mouse intestinal atrophy was evidenced through shortening of epithelial length in the intestine [11] and villi blunting with inflammatory infiltrate present in lamina propria [76], goblet cell depletion, and vacuolization [86]. Besides, a study on gefitinib and icotinib on IEC-6 cells also showed a significant increment in the expression of proinflammatory IL-6 and IL-25 [87]. However, another study using gefitinib showed that ErbB1 ablation in a mouse model of colitis had significantly downregulated the production of IL-33, an inflammatory cytokine in the intestine [88]. An in vitro model using dacomitinib also showed increased monocyte chemotactic protein-1 (MCP1) expression in the ileum, which is an intestinal region in which ErbB1 expression was reported higher in this study [72]. A downstream study on knockdown of RHBD2 gene which involves in activation of the ErbB1 pathway and is responsible for inflammation development in the IL-10-deficient mouse model of colitis displayed intestinal epithelial damage, with elevated neutrophil in the gut [89]. In addition, Xiao et al. proved that LPS-challenged piglets have lower mRNA expression of ErbB1 in the jejunal mucosa region, which strongly supported the correlation activity of downregulation of ErbB1 signalling initiating inflammatory responses [90]. However, such exposures are further required to demonstrate a link between ErbB1 inhibition and intestinal inflammation in lapatinib-induced diarrhoea.

1.5.4. ErbB1 and Intestinal Permeability in TKIs-Induced Diarrhoea. The correlation between ErbB1 and intestinal permeability has been extensively studied, with solid conclusion that activation of ErbB1 signalling adorns intestinal barrier formation through elevated expression of tight junction proteins (TJPs) (claudins, occludins, junctional adhesion molecule-A (JAM-A), and zonula occludens (ZO)), mucin secretion, and enterocyte proliferation enhancement [91]. A healthy intestinal epithelium acts as a barrier which inhibits the permeation of proinflammatory chemicals such as infections and antigens from the luminal environment into mucosal tissue [92]. Disruption of the intestinal barrier, followed by luminal noxious molecule permeability, causes a disruption of the mucosal immune system and inflammation, which can serve as a trigger for the development of intestinal illnesses such as IBD and Crohn’s disease. It is worth highlighting that increased intestinal paracellular permeability was identified as one of the main factors for these fiasco diseases [93, 94].

Tight junctions (TJs) are acknowledged as incredibly dynamic structures that participate in several vital functions of the intestinal epithelium under both normal and pathological settings. Previous studies on ErbB1 signalling have proved to be dependent on TJ formation. For instance, a study using pretreatment of Caco-2, a colon adenocarcinoma cell with EGF, showed a redistribution of TJPs, ZO-1, and occludin, while inhibition of MAPK/Erk has totally abolished the protective effects of EGF on tight junctions (TJs) [95]. Noted here, EGF is a ligand that binds to the ErbB1 receptor, which leads to autophosphorylation activity of receptor tyrosine kinase (RTK) and activation of the downstream pathway of MAPK/Erk and PI3K/Akt, thus stimulating intestinal development [96]. In addition, EGF is mentioned to be a critical regulator of intestinal paracellular permeability, which is dependent on TJ [92]. In this context, inhibition of ErbB1 is stipulated to have an impact on impairment of TJ functions, as this would enhance the invasion of foreign substances into the body and further leakage in intestinal epithelial due to excessive bacterial antigens, thus triggering inflammatory responses [97-99]. This statement is supported by a study using SM-TKI, erlotinib that attenuated paracellular permeability and intestinal atrophy in a gliadin-administered mouse model, accompanied by inhibition of ErbB1 phosphorylation [80]. Administration of simotinib in a Caco-2 model also had reduced expression of afadin-6, a target protein for the ErbB1/Ras/MAPK signalling pathway that interacts with ZO-1 [100]. Furthermore, in another study using intestinal ischemia/reperfusion injury rats, administration of HB-EGF, known as ligand of ErbB1 and ErbB4 in this model, had significantly decreased the intestinal permeability by downregulating proinflammatory markers such as TNF-α, IL-6, and IL-1β [101]. This strongly proved the ability of ErbB1 signalling to protect the intestinal barrier by regulating inflammatory cytokine levels. Besides, exposure of Caco-2 cells to IFN-γ, IL-17A, and zonulin, a protein modulator in the small intestine that rapidly promotes intestinal permeability, demonstrated modification of TJ (ZO-1, claudin-5, and occludin) localization, followed by significant depolymerization of perijunctional F-actin cytoskeleton [102]. An interesting study by Tripathi et al. showed that zonulin, a precursor of haptaglobin-2 (pre-HP2), mediates the transactivation of ErbB1 via protease-activated receptor 2 (PAR2). This couple (pre-HP2/PAR2) modulates the increment in intestinal permeability. At ≥15 μg/mL, single-chain zonulin is able to increase phosphorylation of ErbB1. As such, an in vitro validation test on Caco-2 cells with AG1478 and ErbB1 inhibitor prevented zonulin-induced ErbB1 phosphorylation as well as abolished reduction in transepithelial electrical resistance (TEER) of Caco-2 cells. In addition, zonulin digestion by trypsin dramatically hampered its ability to activate ErbB1 signalling [103]. This study proves that single-chain zonulin, not in its cleaved mature forms, activated ErbB1 through indirect transactivation via PAR2, which initiated TJ disassembly, thus reducing TEER in Caco-2 cells.

Considering all these studies, inhibition of ErbB1 in the intestine by lapatinib is believed to trigger intestinal mucosal damage as well as initiate inflammatory response, together with nutrient malabsorption and histopathological changes. These factors then lead to an increase in intestinal permeability, with such barrier dysfunction having compromised intestinal epithelial TJs in the intestinal epithelium, resulting in diarrhoea. As such,
there is abundant room for further progress in validating this hypothesis of lapatinib-induced diarrhoea.

1.6. Future Directions on Lapatinib-Induced Diarrhoea. Several preliminary in vitro and in vivo models were developed to further clarify the mechanism of diarrhoea related to lapatinib, with various alternative therapeutics having been introduced. However, the aetiology is still unclear with various hypotheses having been discovered related to the GI injury. This review represents the importance of ErbB1 inhibition caused by lapatinib as the most plausible hypothesis to anticipate this GI toxicity. Future research is needed with further deliberation on developing models that incorporate ErbB1 as an imperative indicator of SM-TKI treatment responses.

EGF, as mentioned before, is one of the prominent ligands that activate ErbB1 pathways and has been identified to exhibit a remarkable ability on protecting intestinal epithelium through stimulation of several underlying mechanisms. It is said to be a potent stimulator for epidermal and epithelial cell proliferation [104], regulating cell survival, migration, differentiation, and apoptosis [105]. Besides, EGF is heat-stable [91] and trypsin-resistant [106] and resistant to proteolytic degradation [105], thus making it suitable to be administered through the orogastric route [91]. Recent studies showed that EGF also functions as a gastrointestinal mucosal trophic agent and cryoprotective barrier [107], and its proliferative effect is able to be preserved despite the loss of epidermal growth factor receptor (EGFR) at enterocytes [105]. Moreover, secretion of EGF protein produced by recombinant E. coli Nissle 1917 acts as an in vitro wound healing agent and hastens epithelial migration activity in injured human enterocyte monolayers through activation of the ERK pathway [108]. In short, it is possible to say that cotreatment of lapatinib with recombinant ErbB1 ligands such as EGF would be able to prove whether ErbB1 alteration plays an important role in lapatinib action that leads to side effects such as diarrhoea.

Taken together, these findings might suggest that EGF could be a predictive target for future development of clinical models to uncover the true causation of diarrhoea and hence might be the appropriate therapeutic approach. Though it is apparent that much more must be known about TKI-induced diarrhoea, with persistent study effort, future management of this side effect will be improved vastly.

2. Conclusion

Diarrhoea may seem manageable for a healthy person. However, it can aggravate cancer patients’ QOL as well as compromise their treatment course. Therefore, effective prevention and precise treatment are imperative to reduce the burden of diarrhoea among cancer patients. In this article review, we have discussed the involvement of ErbB1 in SM TKIs-induced diarrhoea, especially by lapatinib, an oral HER2-positive breast cancer treatment. Even though previous research has speculated several hypotheses in the pathogenesis of SM TKIs-induced diarrhoea, we hypothesise that inhibition of ErbB1 in a normal intestine may play a role in this gastrointestinal toxicity. It is worth highlighting that there is still obscurity as to whether increased intestinal permeability is a result of the inflammatory response or a pathophysiologic predictor of disease. It is hoped that determining whether excessive intestinal permeability is the product of a continuing inflammatory response or whether the intestinal barrier function contributes to the diarrhoea progression will be critical to our knowledge of LID pathophysiology. As such, understanding of this mechanism would provide new insights and new directions to prevent and minimize the incidence subsequently towards novel intervention for diarrhoea prevention and improving patient’s QOL.

Abbreviations

5-FU: 5-Fluorouracil
AEs: Adverse effects
Apc: Adenomatous polyposis coli
AREG: Amphiregulin
ASCO: American Society and Clinical Oncology
ATP: Adenosine triphosphate
BRAT: Banana, rice, applesauce, and toast
BTC: Betacellulin
CaCC: Calcium-activated chloride channels
Caco-2: Colorectal adenocarcinoma cells
CFTR: Cystic fibrosis transmembrane conductance regulator
CID: Chemotherapy-induced diarrhoea
DSS: Dextran-sulphate sodium
EGF: Epidermal growth factor
EGFR: Epidermal growth factor receptor
EPI: Epigenin
EREG: Epiregulin
ERK/Ras: Extracellular signal-regulated kinase/protooncogene protein P21
ESMO: European Society for Medical Oncology
GI: Gastrointestinal
GIT: Gastrointestinal tract
HB-EGF: Heparin-binding EGF-like growth factor
HNSCC: Head and neck squamous cell carcinoma
IBD: Inflammatory bowel disease
IC<sub>50</sub>: Half-maximal inhibitory concentration
IEC-6: Intestinal epithelioid cell no. 6
IFN-δ: Interferon-gamma
IFN-α: Interferon-alpha
IL-1: Interleukin-1
IL-25: Interleukin-25
IL-33: Interleukin-33
IL-4: Interleukin-4
IL-6: Interleukin-6
ISC: Intestinal stem cells
JAM-A: Junction adhesion molecule-A
LPS: Lipopolysaccharide
mAbs: Monoclonal antibodies
MAPK/Erk: Mitogen-activated protein kinase/extracellular signal-regulated kinase
MCP1: Monocyte chemoattractant protein-1
NF-κB: Nuclear factor
References

[1] H. R. Wardill, J. M. Bowen, and R. J. Gibson, “Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?,” Cancer Chemotherapy and Pharmacology, vol. 70, no. 5, pp. 627–635, 2012.

[2] C. Frankel and F. M. Palmieri, “Lapatinib side-effect management,” Clinical Journal of Oncology Nursing, vol. 14, no. 2, pp. 223–233, 2010.

[3] R. M. McQuade, V. Stojanovska, R. Abalo, J. C. Bornstein, and K. Nurgali, “Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments,” Frontiers in pharmacology, vol. 7, p. 414, 2016.

[4] B. Moy, P. Kirkpatrick, S. Kar, and P. Goss, “Lapatinib,” Nature Reviews Drug Discovery, vol. 6, no. 6, pp. 431–432, 2007.

[5] K. R. Secombe, Y. Van Sebille, B. J. Mayo, J. K. Coller, R. J. Gibson, and J. M. Bowen, “Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome,” Integrative Cancer Therapies, vol. 19, 2020.

[6] H. A. Azim, D. Agbor-Tarh, I. Bradbury et al., “Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial,” Journal of Clinical Oncology, vol. 31, no. 36, pp. 4504–4511, 2013.

[7] V. D’Amato, L. Raimondo, L. Formisano et al., “Mechanisms of lapatinib resistance in HER2-driven breast cancer,” Cancer Treatment Reviews, vol. 41, no. 10, pp. 877–883, 2015.

[8] B. J. Mayo, K. R. Secombe, A. D. Wignall et al., “The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats,” Cancer Chemotherapy and Pharmacology, vol. 85, no. 4, pp. 793–803, 2020.

[9] N. Al-Dassoqi, S. T. Sonis, J. M. Bowen et al., “Emerging evidence on the pathobiology of mucositis,” Supportive Care in Cancer, vol. 21, no. 7, pp. 2075–2083, 2013.

[10] W. N. I. Wan Mohamad Zain, J. Bowen, E. Bateman, and D. Keefe, “Cytotoxic effects of the dual ErbB tyrosine kinase inhibitor, lapatinib, on Walker 256 rat breast tumour and IEC-6 rat normal small intestinal cell lines,” Biomedicine, vol. 8, no. 1, p. 2, 2020.

[11] J. J. Freeman, Y. Feng, F. R. Demehri, P. J. Dempsey, and D. H. Teitelbaum, “TPN-associated intestinal epithelial cell atrophy is modulated by TLR4/EGF signaling pathways,” The FASEB Journal, vol. 29, no. 7, pp. 2943–2958, 2015.

[12] J. M. Bowen, B. J. Mayo, E. Plews et al., “Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea,” Cancer Biology & Therapy, vol. 13, no. 13, pp. 1269–1275, 2012.

[13] Z. Wang, “ErbB receptors and cancer,” in ErbB Receptor Signaling, Z. Wang, Ed., vol. 1652 of Methods in Molecular Biology, Humana Press, New York, NY, 2017.

[14] D. J. Riese, R. M. Gallo, and J. Settleman, “Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis,” BioEssays, vol. 29, no. 6, pp. 558–565, 2007.

[15] B. A. Hemmings and D. F. Restuccia, “PI3K-PKB/Akt pathway,” Cold Spring Harbor perspectives in biology, vol. 4, no. 9, article a011189, 2012.

[16] W. Zhang and H. T. Liu, “MAPK signal pathways in the regulation of cell proliferation in mammalian cells,” Cell Research, vol. 12, no. 1, pp. 9–18, 2002.

[17] P. Wee and Z. Wang, “Epidermal growth factor receptor cell proliferation signaling pathways,” Cancers, vol. 9, no. 5, p. 52, 2017.

[18] M. J. Wieduwilt and M. M. Moasser, “The epidermal growth factor receptor family: biology driving targeted therapeutics,” Cellular and Molecular Life Sciences, vol. 65, no. 10, pp. 1566–1584, 2008.

[19] E. Rossi, S. Grisanti, V. Villanacci et al., “HER-2 overexpression/amplification in Barrett’s oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinicopathologic study,” Journal of Cellular and Molecular Medicine, vol. 13, no. 9b, pp. 3826–3833, 2009.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

RNFSRS and WNIWMZ performed the review search, read the cited articles, wrote this review, prepared all the tables/figures, responded to the reviewer comments, and modified the references for citation style. JK, MJJ, MM, and JB contributed by critically reviewing this article. All authors approved the final manuscript.

Acknowledgments

The authors would like to acknowledge the Ministry of Higher Education, Malaysia for Fundamental Research Grant Scheme funding: 600-IRMI/FRGS-RACER 5/3 (018/2019).

NKG1: Neuregulin-1
NKG4: Neuregulin-4
NKGs: Neuregulins
NSCLC: Non-small-cell lung cancer
PAR2: Protease-activated receptor 2
PI3K: Phosphatidylinositol-3′-kinases
PLCγ1: Phosphoinositide phospholipase C-γ1
Pre-HP2: Precursor of haptaglobin-2
QOL: Quality of life
RHBD2: Rhomboid 5 homolog 2
SM-TKIs: Small molecule tyrosine kinase inhibitors
SN38: 7-Ethyl-10-hydroxycamptothecin
STAT/Src: Signal transducer and activator of transcription proteins/Src
T790M: Threonine790Methionine mutation
TEER: Transepithelial electrical resistance
TGF-α: Transforming growth factor-alpha
TJP: Tight junction protein
TJPs: Tight junction proteins
TJs: Tight junctions
TKIs: Tyrosine kinase inhibitors
TLR: Toll-like receptor
TNF-α: Tumour necrosis factor-alpha
Vd: Volume of distribution
ZO: Zonula occludens
ZO-1: Zonula occludens-1.
ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway, *Oncology Reports*, vol. 39, no. 6, pp. 2892–2898, 2018.

H. E. Abud, W. H. Chan, and T. Jardé, “Source and impact of the EGF family of ligands on intestinal stem cells,” *Frontiers in Cell and Developmental Biology*, vol. 9, article 685665, 2021.

E. M. Holloway, M. Czerwinsky, Y. H. Tsai et al., “Mapping development of the human intestinal niche at single-cell resolution,” *Cell Stem Cell*, vol. 28, no. 3, pp. 568–580.e4, 2021.

T. Jardé, W. H. Chan, F. J. Rossello et al., “Mesenchymal niche-derived neuregulin-1 drives intestinal stem cell proliferation and regeneration of damaged epithelium,” *Cell Stem Cell*, vol. 27, no. 4, pp. 646–662.e7, 2020.

J. K. Bernard, S. P. McCann, V. Bhardwaj, M. K. Washington, and M. R. Frey, “Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo,” *The Journal of Biological Chemistry*, vol. 287, no. 47, pp. 39850–39858, 2012.

C. S. Williams, J. K. Bernard, M. Demory Beckler et al., “ERBB4 is over-expressed in human colon cancer and enhances cellular transformation,” *Carcinogenesis*, vol. 36, no. 7, pp. 710–718, 2015.

D. Almohazez and M. R. Frey, “The intestinal stem cell niche and its regulation by ErbB growth factor receptors,” in *Stem Cells, Tissue Engineering and Regenerative Medicine*, pp. 273–294, World Scientific, 2015.

M. R. Frey, K. E. Edelblum, M. T. Mullane, D. Liang, and D. B. Polk, “The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF,” *Gastroenterology*, vol. 136, no. 1, pp. 217–226, 2009.

A. T. Nguyen, S. Y. Lee, H. J. Chin, Q. V. Le, and D. Lee, “Kinase activity of ERBB3 contributes to intestinal organoid growth and intestinal tumorigenesis,” *Cancer Science*, vol. 111, no. 1, pp. 137–147, 2020.

N. E. Hynes and G. MacDonald, “ErbB receptors and signaling pathways in cancer,” *Current Opinion in Cell Biology*, vol. 21, no. 2, pp. 177–184, 2009.

A. S. Hervent and G. W. De Keulenaer, “Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics,” *International Journal of Molecular Sciences*, vol. 13, no. 12, pp. 12268–12286, 2012.

W. Q. Cai, L. S. Zeng, L. F. Wang et al., “The latest battles between EGFR monoclonal antibodies and resistant tumor cells,” *Frontiers in Oncology*, vol. 10, p. 1249, 2020.

S. S. Kanwar, J. Nautiyal, and A. P. N. Majumdar, “EGFR (S) inhibitors in the treatment of gastro-intestinal cancers: what’s new?,” *Current Drug Targets*, vol. 11, no. 6, pp. 682–698, 2010.

J. T. Hartmann, M. Haap, H. G. Kopp, and H. P. Lipp, “Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects,” *Current Drug Metabolism*, vol. 10, no. 5, pp. 470–481, 2009.

A. Appert-Coltin, P. Hubert, G. Crémel, and A. Bennasroune, “Role of ErbB receptors in cancer cell migration and invasion,” *Frontiers in pharmacology*, vol. 6, pp. 283, 2015.

D. F. Stern, “Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases,” *Breast Cancer Research*, vol. 2, no. 3, pp. 176–183, 2000.

A. J. van der Wekken, J. L. Kuiper, A. Saber et al., “Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression,” *PLoS One*, vol. 12, no. 8, article e0182885, 2017.

B. B. Yang, P. Lum, A. Chen et al., “Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab,” *Clinical Pharmacokinetics*, vol. 49, no. 11, pp. 729–740, 2010.

M. V. Cantarini, T. McFarquhar, R. P. Smith, C. Bailey, and A. L. Marshall, “Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers,” *Clinical Therapeutics*, vol. 26, no. 10, pp. 1630–1636, 2004.

Y. L. Teo, H. K. Ho, and A. Chan, “Metabolism-related pharmacokinetic drug–drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations,” *British Journal of Clinical Pharmacology*, vol. 79, no. 2, pp. 241–253, 2015.

C. C. Ogu and J. L. Maxa, “Drug interactions due to cytochrome P450,” *Baylor University Medical Center Proceedings*, vol. 13, no. 4, pp. 421–423, 2000.

R. J. Keizer, A. D. R. Huijtena, J. H. M. Schellens, and J. H. Beijnen, “Clinical pharmacokinetics of therapeutic monoclonal antibodies,” *Clinical Pharmacokinetics*, vol. 49, no. 8, pp. 493–507, 2010.

S. Bian, X. Tang, and W. Lei, “A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin,” *BMC Pulmonary Medicine*, vol. 20, no. 1, p. 181, 2020.

F. Broekman, E. Giovannetti, and G. J. Peters, “Tyrosine kinase inhibitors: multi-targeted or single-targeted?,” *World Journal of clinical oncology*, vol. 2, no. 2, pp. 80–93, 2011.

H. Cheng and T. Force, “Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics,” *Circulation Research*, vol. 106, no. 1, pp. 21–34, 2010.

D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” *The New England Journal of Medicine*, vol. 351, no. 4, pp. 337–345, 2004.

K. Nakata, T. Komori, K. Saso et al., “Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer,” *International Journal of Colorectal Disease*, vol. 36, no. 12, pp. 2621–2627, 2021.

S. Rawat, H. Tandan, S. Patel, and S. Chaudhari, “Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: an Indian rural hospital experience,” *South Asian Journal of Cancer*, vol. 8, no. 1, pp. 52–56, 2019.

B. Besse, F. Barlesi, I. Demedts et al., “A phase Ib study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer,” *Lung Cancer*, vol. 137, no. 137, pp. 136–143, 2019.

O. Fiala, P. Hosek, M. Pesek et al., “Serum concentration of erlotinib and its correlation with outcome and toxicity in patients with advanced-stage NSCLC,” *Anticancer Research*, vol. 37, no. 11, pp. 6469–6476, 2017.

M. Kimura, F. Yasue, E. Usami et al., “Clinical pharmacokinetics of therapeutic monoclonal antibodies,” *Clinical Pharmacokinetics*, vol. 26, no. 10, pp. 1630–1636, 2004.

J. Xu, L. Gong, Z. Qian, G. Song, and J. Liu, “ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway,” *Oncology Reports*, vol. 39, no. 6, pp. 2892–2898, 2018.
[51] K. Nakagawa, E. B. Garon, T. Seto et al., “Ramucirumab plus erlotinib in patients with untreated, _EGFR_ -mutated, advanced non-small-cell lung cancer (RELAY): a randomly allocated, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 20, no. 12, pp. 1655–1669, 2019.

[52] E. de Azambuja, A. P. Holmes, M. Piccart-Gebhart et al., “Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response,” The Lancet Oncology, vol. 15, no. 10, pp. 1137–1146, 2014.

[53] J. Mortimer, J. Di Palma, K. Schmid, Y. Ye, and M. Jahanzeb, “Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial,” Breast Cancer Research, vol. 21, no. 1, p. 32, 2019.

[54] W. C. Kwok, T. C. C. Tam, and D. C. L. Lam, “First reported case of afatinib-associated toxic megacolon,” Respirology Case Reports, vol. 6, no. 7, article e00360, 2018.

[55] Y. L. Wu, Y. Cheng, X. Zhou et al., “Dacomitinib versus gefitinib as first-line treatment for patients with _EGFR_ -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial,” The Lancet Oncology, vol. 18, no. 11, pp. 1454–1466, 2017.

[56] S. L. Greig, “Osimertinib: first global approval,” Drugs, vol. 76, no. 2, pp. 263–273, 2016.

[57] A. Lee, “Tucatinib: first approval,” Drugs, vol. 80, no. 10, pp. 1033–1038, 2020.

[58] H. S. Rugo, J. A. Di Palma, D. Tripathy et al., “The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea,” Breast Cancer Research and Treatment, vol. 175, pp. 5–15, 2019.

[59] R. J. Gibson and A. M. Stringer, “Chemotherapy-induced diarrhoea,” Current Opinion in Supportive and Palliative Care, vol. 3, no. 1, pp. 31–35, 2009.

[60] G. Whittaker and J. Newman, “Loperamide: an emerging drug of abuse and cause of prolonged QTc,” Clinical Medicine, vol. 21, no. 2, pp. 150–152, 2021.

[61] U. Demirci, S. Buyukberber, G. Yilmaz et al., “Hepatotoxicity associated with lapatinib in an experimental rat model,” European Journal of Cancer, vol. 48, no. 2, pp. 279–285, 2012.

[62] M. Segovia-Mendoza, M. E. González-González, D. Barrera, L. Díaz, and R. García-Becerra, “Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence,” American Journal of Cancer Research, vol. 5, no. 9, pp. 2531–2561, 2015.

[63] Z. A. Wainberg, A. Anghel, A. J. Desai et al., “Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibitsHER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo,” Clinical Cancer Research, vol. 16, no. 5, pp. 1509–1519, 2010.

[64] Z. Xiang, S. Song, Z. Zhu et al., “LncRNAs GIHCG and SPINT1-AS1 are crucial factors for pan-cancer cells sensitivity to lapatinib,” Frontiers in Genetics, vol. 10, p. 25, 2019.

[65] A. C. Sandoval-Leon, R. Mahtani, and M. Jahanzeb, “Chapter 7- adjuvant therapy,” in _Her2-Positive Breast Cancer_, S. Hurvitz and K. McCann, Eds., pp. 107–118, Elsevier, Philadelphia, 2019.

[66] M. M. Mader and J. R. Henry, “7.03 - Antimetabolites,” in _Comprehensive Medicinal Chemistry II_, J. B. Taylor and D. J. Triggle, Eds., pp. 55–79, Elsevier, Oxford, 2007.

[67] J. M. Bowen, “Mechanisms of TKI-induced diarrhea in cancer patients,” Current Opinion in Supportive and Palliative Care, vol. 7, no. 2, pp. 162–167, 2013.

[68] C. Dang, N. Lin, B. Moy et al., “Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu–overexpressed/amplified breast cancer is not feasible because of excessive diarrhea,” Journal of Clinical Oncology, vol. 28, no. 18, pp. 2982–2988, 2010.

[69] M. O. Jamil, M. Rizwan, and J. T. Carpenter, “Propylphylactic use of anti-diarrheal agents to control diarrhea associated with lapatinib therapy in breast cancer patients,” vol. 33, no. 29, pp. 205–205, 2015.

[70] J. M. Bowen, B. J. Mayo, E. Plews et al., “Determining the mechanisms of lapatinib-induced diarrhoea using a rat model,” Cancer Chemotherapy and Pharmacology, vol. 74, no. 3, pp. 617–627, 2014.

[71] Y. Kim, A. Quach, S. Das, and K. E. Barrett, “Potentiation of calcium-activated chloride secretion and barrier dysfunction may underlie EGF receptor tyrosine kinase inhibitor-induced diarrhea,” Physiological reports, vol. 8, no. 13, article e14490, 2020.

[72] Y. Z. A. V. Sebille, R. J. Gibson, H. R. Wardill et al., “Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats,” International Journal of Cancer, vol. 140, no. 12, pp. 2820–2829, 2017.

[73] Y. Z. A. V. Sebille, R. J. Gibson, H. R. Wardill, I. A. Ball, D. M. K. Keefe, and J. M. Bowen, “Dacomitinib-induced diarrhea: targeting chloride secretion with crofelemer,” International Journal of Cancer, vol. 142, no. 2, pp. 369–380, 2018.

[74] K. J. Hare, B. Hartmann, H. Kissow, J. J. Holst, and S. S. Poulsen, “The intestinotrophic peptide, GLP-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib,” Clinical Cancer Research, vol. 13, no. 17, pp. 5170–5175, 2007.

[75] R. B. Roberts, C. L. Arteaga, and D. W. Threadgill, “Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies,” Cancer Cell, vol. 5, no. 2, pp. 115–120, 2004.

[76] K. R. Scombe, I. A. Ball, J. Shirren et al., “Targeting neratinib-induced diarrhea with budesonide and colesvelam in a rat model,” Cancer Chemotherapy and Pharmacology, vol. 83, no. 3, pp. 531–543, 2019.

[77] N. J. Gurule, C. E. McCoach, T. K. Hinz et al., “A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer,” NPL precision oncology, vol. 5, no. 1, p. 41, 2021.

[78] M. E. Lacouture, E. P. Mitchell, B. Pipersdi et al., “Skin toxicity evaluation protocol with panitumumab (STEPPE), a phase II, open-label, randomized trial evaluating the impact of a pre-Empite skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1351–1357, 2010.

[79] A. O. Leech, S. H. Vellanki, E. J. Rutherford et al., “Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings,” Breast Cancer Research, vol. 20, no. 1, p. 140, 2018.
[80] S. Shimada, T. Tanigawa, T. Watanabe et al., “Involvement of gliadin, a component of wheat gluten, in increased intestinal permeability leading to non-steroidal anti-inflammatory drug-induced small-intestinal damage,” PlasOne, vol. 14, no. 2, p. e0211436, 2019.

[81] N. Bertiaux-Vandaelle, S. B. Youmaba, L. Belmonte et al., “The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype,” The American Journal of Gastroenterology, vol. 106, no. 12, pp. 2165–2173, 2011.

[82] A. M. Stringer, R. J. Gibson, R. M. Logan et al., “Irinotecan-induced mucositis is associated with changes in intestinal mucus,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 1, pp. 123–132, 2009.

[83] R. J. Gibson, J. M. Bowen, M. R. B. Inglis, A. G. Cummins, and D. M. K. Keefe, “Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer,” Journal of Gastroenterology and Hepatology, vol. 18, no. 9, pp. 1095–1100, 2003.

[84] T. Liu, L. Zhang, D. Joo, and S. C. Sun, “NF-xB signaling in inflammation,” Signal Transduction and Targeted Therapy, vol. 2, p. 17023, 2017.

[85] H. R. Wardill, R. J. Gibson, R. M. Logan, and J. M. Bowen, “TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity,” International Journal of Cancer, vol. 135, no. 11, pp. 2483–2492, 2014.

[86] L. Qu, W. Tan, J. Yang et al., “Combination compositions composed of l-glutamine and Si-Jun-Zi-Tang might be a preferable choice for 5-fluorouracil-induced intestinal mucositis: an exploration in a mouse model,” Frontiers in Pharmacology, vol. 11, p. 918, 2020.

[87] S. Hong, Y. Gu, Z. Gao et al., “EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells,” Life Sciences, vol. 119, no. 1–2, pp. 28–33, 2014.

[88] M. S. Islam, K. Horiguchi, S. Iino et al., “Epidermal growth factor is a critical regulator of the cytokine IL-33 in intestinal epithelial cells,” British Journal of Pharmacology, vol. 173, no. 16, pp. 2532–2542, 2016.

[89] R. Geesala, W. Schanz, M. Biggs et al., “Loss of RHBDL2 results in an early-onset spontaneous murine colitis,” Journal of Leukocyte Biology, vol. 105, no. 4, pp. 767–781, 2019.

[90] K. Xiao, S. T. Cao, L. F. Jiao, F. H. Lin, L. Wang, and C. H. Hu, “Anemonin improves intestinal barrier restoration and influences TGF-β1 and EGFR signaling pathways in LPS-challenged piglets,” Innate Immunity, vol. 22, no. 5, pp. 344–352, 2016.

[91] X. Tang, H. Liu, S. Yang, Z. Li, J. Zhong, and R. Fang, “Epidermal growth factor and intestinal barrier function,” Mediators of Inflammation, vol. 2016, Article ID 1927348, 2016.

[92] S. H. Lee, “Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases,” Intestinal Research, vol. 13, no. 1, pp. 11–18, 2015.

[93] J. Z. H. von Martels, A. R. Bourgonje, H. J. M. Harmesen, K. N. Faber, and G. Dijkgra, “Assessing intestinal permeability in Crohn’s disease patients using orally administered 52Cr-EDTA,” PlasOne, vol. 14, no. 2, article e0211973, 2019.

[94] W. Turpin, S. H. Lee, J. A. Raygoza Garay et al., “Increased intestinal permeability is associated with later development of Crohn’s disease,” Gastroenterology, vol. 159, no. 6, pp. 2092–2100.e5, 2020.

[95] S. Basuroy, A. Seth, B. Elias, A. P. Naren, and R. Rao, “MAPK interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide,” The Biochemical Journal, vol. 393, no. 1, pp. 69–77, 2006.

[96] A. Bedford, T. Chen, E. Huynh et al., “Epidermal growth factor containing culture supernatant enhances intestine development of early-weaned pigs in vivo: potential mechanisms involved,” Journal of Biotechnology, vol. 196-197, no. 196–197, pp. 9–19, 2015.

[97] C. T. Capaldeo, D. N. Powell, and D. Kalman, “Layered defense: how mucus and tight junctions seal the intestinal barrier,” Journal of Molecular Medicine, vol. 95, no. 9, pp. 927–934, 2017.

[98] S. M. Krug, J. D. Schulzke, and M. Fromm, “Tight junction, selective permeability, and related diseases,” Seminars in Cell & Developmental Biology, vol. 36, no. 36, pp. 166–176, 2014.

[99] M. J. Zhu, X. Sun, and M. Du, “AMPK in regulation of apical junctions and barrier function of intestinal epithelium,” Tissue Barriers, vol. 6, no. 2, pp. 1–13, 2018.

[100] Q. Zhu, Z. Liu, P. Li, and Z. Cheng, “Drug interaction studies reveal that simotinib upregulates intestinal absorption by increasing the paracellular permeability of intestinal epithelial cells,” Drug Metabolism and Pharmacokinetics, vol. 29, no. 4, pp. 317–324, 2014.

[101] D. V. Rocourt, V. B. Mehta, and G. E. Besner, “Heparin-binding EGF-like growth factor decreases inflammatory cytokine expression after intestinal ischemia/reperfusion injury,” The Journal of Surgical Research, vol. 139, no. 2, pp. 269–273, 2007.

[102] M. T. Rahman, C. Ghosh, M. Hossain et al., “IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases,” Biochemical and Biophysical Research Communications, vol. 507, no. 1-4, pp. 274–279, 2018.

[103] A. Tripathi, K. M. Lamners, S. Goldblum et al., “Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2,” PNAS, vol. 106, no. 39, pp. 16799–16804, 2009.

[104] M. J. Kim, R. M. Jun, W. K. Kim et al., “Optimal concentration of human epidermal growth factor (hEGF) for epithelial healing in experimental corneal alkali wounds,” Current Eye Research, vol. 22, no. 4, pp. 272–279, 2001.

[105] K. J. Rowland, P. M. Choi, and B. W. Warner, “The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis,” Seminars in Pediatric Surgery, vol. 22, no. 2, pp. 101–111, 2013.

[106] C. J. Chang and J. C. J. Chao, “Effect of human milk and epidermal growth factor on growth of human intestinal Caco-2 cells,” Journal of Pediatric Gastroenterology and Nutrition, vol. 34, no. 4, pp. 394–401, 2002.

[107] P. Arda-Pirincici and S. Bolkent, “The role of epidermal growth factor in prevention of oxidative injury and apoptosis induced by intestinal ischemia/reperfusion in rats,” Acta Histochemica, vol. 116, no. 1, pp. 167–175, 2014.

[108] H. J. Choi, J. H. Ahn, S. H. Park, K. H. Do, J. Kim, and Y. Moon, “Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics,” Infection and Immunity, vol. 80, no. 3, pp. 1079–1087, 2012.